Page last updated: 2024-10-30

metformin and Leanness

metformin has been researched along with Leanness in 11 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene."7.83A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016)
"The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)."7.74Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007)
"This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)."7.73Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005)
"Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well."7.73The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005)
"Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene."3.83A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016)
" Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice."3.78Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012)
"The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)."3.74Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007)
"This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)."3.73Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005)
"Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well."3.73The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005)
"Type 2 diabetes is characterized by insulin resistance, hyperinsulinemia and hepatic overproduction of glucose and lipids."1.48Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance. ( Cleland, C; Farese, RV; Foufelle, F; Lee, MC; Sajan, J; Sajan, MP, 2018)
"Obesity-driven Type 2 diabetes (T2D) is a systemic inflammatory condition associated with cardiovascular disease."1.48Inflammatory signatures distinguish metabolic health in African American women with obesity. ( Andrieu, G; Bertrand, KA; Denis, GV; Medina, ND; Palmer, JR; Sebastiani, P; Slama, J; Strissel, KJ; Tran, AH, 2018)
"Insulin resistance was assessed by 3-h oral glucose tolerance test (OGTT)."1.46Metabolic and androgen profile in underweight women with polycystic ovary syndrome. ( Anastasiou, OE; Canbay, A; Fuhrer, D; Reger-Tan, S, 2017)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anastasiou, OE1
Canbay, A1
Fuhrer, D1
Reger-Tan, S1
Sajan, MP1
Lee, MC1
Foufelle, F1
Sajan, J1
Cleland, C1
Farese, RV1
Denis, GV1
Sebastiani, P1
Bertrand, KA1
Strissel, KJ1
Tran, AH1
Slama, J1
Medina, ND1
Andrieu, G1
Palmer, JR1
Shigiyama, F1
Kumashiro, N1
Rikitake, T1
Usui, S1
Saegusa, M1
Kitamura, M1
Uchino, H1
Hirose, T1
Bedford, DC1
Kasper, LH1
Wang, R1
Chang, Y1
Green, DR1
Brindle, PK1
Cinar, N1
Harmanci, A1
Bayraktar, M1
Yildiz, BO1
Leiria, LO1
Sollon, C1
Calixto, MC1
Lintomen, L1
Mónica, FZ1
Anhê, GF1
De Nucci, G1
Zanesco, A1
Grant, AD1
Antunes, E1
Kumari, AS1
Haq, A1
Jayasundaram, R1
Abdel-Wareth, LO1
Al Haija, SA1
Alvares, M1
Yilmaz, M1
Biri, A1
Karakoç, A1
Törüner, F1
Bingöl, B1
Cakir, N1
Tiras, B1
Ayvaz, G1
Arslan, M1
Tan, S1
Hahn, S1
Benson, S1
Dietz, T1
Lahner, H1
Moeller, LC1
Schmidt, M1
Elsenbruch, S1
Kimmig, R1
Mann, K1
Janssen, OE1
Al-Ozairi, E1
Quinton, R1
Advani, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau[NCT05591339]Phase 4200 participants (Anticipated)Interventional2023-03-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

11 other studies available for metformin and Leanness

ArticleYear
Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
    Archives of gynecology and obstetrics, 2017, Volume: 296, Issue:2

    Topics: Adult; Androgens; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Ag

2017
Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
    Cellular signalling, 2018, Volume: 43

    Topics: Adult; Aged; Animals; Cyclopentanes; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Forkhead Box

2018
Inflammatory signatures distinguish metabolic health in African American women with obesity.
    PloS one, 2018, Volume: 13, Issue:5

    Topics: Biomarkers; Black or African American; Chemokines; Cytokines; Diabetes Mellitus, Type 2; Female; Gly

2018
A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin.
    Endocrine journal, 2016, Volume: 63, Issue:2

    Topics: Adult; Diabetes Mellitus, Type 1; Disease Progression; Female; Humans; Hypoglycemic Agents; Metformi

2016
Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.
    Cell metabolism, 2011, Aug-03, Volume: 14, Issue:2

    Topics: Animals; Blood Glucose; Cells, Cultured; CREB-Binding Protein; Diet; Energy Metabolism; Female; Gluc

2011
Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
    Clinical endocrinology, 2013, Volume: 78, Issue:3

    Topics: Androstenes; Ethinyl Estradiol; Female; Humans; Male; Metformin; Middle Aged; Polycystic Ovary Syndr

2013
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal

2012
Metformin monotherapy in lean women with polycystic ovary syndrome.
    Reproductive biomedicine online, 2005, Volume: 10, Issue:1

    Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Thinness

2005
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Journal of endocrinological investigation, 2005, Volume: 28, Issue:11

    Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu

2005
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
    European journal of endocrinology, 2007, Volume: 157, Issue:5

    Topics: Body Weight; Female; Humans; Insulin Resistance; Metformin; Obesity; Overweight; Polycystic Ovary Sy

2007
Therapeutic response to metformin in an underweight patient with polycystic ovarian syndrome.
    Fertility and sterility, 2008, Volume: 90, Issue:4

    Topics: Adult; Female; Fetal Proteins; Humans; Hypoglycemic Agents; Insulin; Menstrual Cycle; Metformin; Pol

2008